New program aims to ease lymphoma Survivors' fear of recurrence
NCT ID NCT05080166
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a program called UPLYFT designed to help lymphoma survivors who have finished treatment cope with the fear that their cancer might return. The program provides information and tools to improve quality of life and reduce worry. Researchers will first gather feedback from clinicians and then test the program with about 74 survivors to see if it is feasible and acceptable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) - a behavioral intervention
What this could lead to
If successful, this could provide a structured program to help lymphoma survivors cope with fear of cancer returning and improve their daily well-being.
What could go wrong
This is a very early pilot study with only 74 participants, focused on feasibility and feedback. It is not designed to prove the program works, and results may not apply to all survivors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact